Wire transfer from Dr. Gruber, the same scientist with one other her deputy, Dr. Philip Krause, who resigned from FDA; recall that; here is a wire transfer of near 3 million to FDA from Pfizer; hhhhmm
palexander.substack.com
Discover more from Alexander COVID News-Dr. Paul Elias Alexander's Newsletter
COVID-19 and SARS-CoV-2: natural immunity; innate immunity; vaccines and immune pressure; no vaccines for children; early outpatient treatment; lockdowns; school closures and mask mandates and vaccine mandates and emergency powers and truck convoy
Over 38,000 subscribers
Continue reading
Wire transfer from Dr. Gruber, the same scientist with one other her deputy, Dr. Philip Krause, who resigned from FDA; recall that; here is a wire transfer of near 3 million to FDA from Pfizer; hhhhmm
Some say that this is a pharma vaccine company bribing the US government, the FDA...what do you think? why then did Gruber resign? Did she realize that the vaccine was ineffective, unsafe? when?
What did Gruber and Krause know, and when did they know it? you see, all of these types of questions must be answered with public inquiries in legal settings, all involved…must answer and if they did nothing wrong, we hug them, but if their decisions costed lives, we must lock them up! I want Dr. Francis Collins investigated. For each and everything he and Fauci did together…each.
Wire transfer from Dr. Gruber, the same scientist with one other her deputy, Dr. Philip Krause, who resigned from FDA; recall that; here is a wire transfer of near 3 million to FDA from Pfizer; hhhhmm
These people all must be dragged out of the black holes they came from and are trying to scurry back to. They need to have their eyes taped open, and then we need to roll the film of the horrors that they wrought upon us. Anything less will allow them to do this over and over and over again.
https://bherr.substack.com/p/the-fallout-is-real?s=w
Companies pay the FDA at the time they submit a marketing application. This is true for all products regulated by the FDA's centers CBER and CDER. This has been in place since about 1996 and was put in place to increase the fda's resources and expedite the approval of new therapies. In other countries, companies pay fees to the regulatory authorities to review each clinical trial that they run. In the United States the cost is backended to the time they file the marketing application. There's definitely an argument to be made about whether this is appropriate or not. But on the face of it, there's nothing illegal or unethical about this letter in light of the current regulations.